BACKGROUND: The treatment of @entity2946 has changed considerably during the last decades. Treatment differences between centers may affect a multicenter analysis. We analyzed data from @entity1 of a single institution gathered over a long period of time. @entity1 : Between 1968 and 1995, 60 @entity1 with @entity2946 were treated at the University of Munster. Thirty-six were male, 24-female. The ages ranged between 11 months and 32 years. METHODS: Data were retrospectively analyzed from files. Survival was estimated using the Kaplan Meier method and compared using the logranktest and multivariance analysis. RESULTS: The 5-year survival rate was 37%. This included an early mortality of 20% within the first two months, prior to 1980. Significant single, positive, prognostic factors included: no solid metastases (p = 0.001), age > 10 years (p < 0.002); total resection (p < 0.025); posterior fossa radiation with more than 50 Gy (p = 0.04); and intense chemotherapy (p = 0.02). Male @entity1 did slightly worse (not significant). The three-year event-free survival rate of 16 @entity1 treated after 1991 was 70%. CONCLUSION: The prognosis of @entity2946 has clearly improved with the reduction of the perioperative mortality, standardized radiotherapy, and the introduction of intense chemotherapy.

XXXX : experience of a single institution.

@entity1 :: ('9606', 'Species') :: ['PATIENTS', 'patients'] @entity2946 :: ('MESH:D008527', 'Disease') :: ['medulloblastoma']
@entity2946 :: (MESH:D008527,Disease) :: ['Medulloblastoma']
